Amgen and Entera Bio call off oral drug delivery partnership after four years

Amgen and Entera Bio are calling off a four-year research collaboration “out of mutual convenience,” Entera revealed in its first-quarter results. The Jerusalem-based biotech is developing new ways to administer macromolecules orally, which is expected to allow patients to skip injections.  When Amgen put down $725,000 in early 2019 for…

Click to view original post